Targeting hyperglucagonaemia in T2DM

被引：1

|

作者：

Starling S.

机构：

[1] Nature Reviews Endocrinology,

来源：

Nature Reviews Endocrinology | 2022年 / 18卷 / 7期

关键词：

D O I：

10.1038/s41574-022-00694-3

中图分类号：

学科分类号：

摘要：

[No abstract available]

引用

收藏

页码：393 / 393

相关论文

共 50 条

[21] Benefits of rosiglitazone in children with T2DM
Dabiri, G
Jones, K
Krebs, J
Sun, YJ
Mudd, P
Weston, WM
Cobitz, AR
Freed, MI
Porter, LE
[J]. DIABETES, 2005, 54 : A457 - A458
[22] Heart Failure Challenge in T2DM
Elmaraghi, Osama
[J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0D)
[23] Defining genetic risk of T2DM
Greenhill, Claire
[J]. NATURE REVIEWS ENDOCRINOLOGY, 2019, 15 (08) : 438 - 438
[24] Microbial metabolite linked to T2DM
Morris, Alan
[J]. NATURE REVIEWS ENDOCRINOLOGY, 2018, 15 (01) : 3 - 3
[25] THE ROLE OF THE STOMACH IN THE ETIOLOGY OF T2DM
Pories, W. J.
[J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2013, 15 : A18 - A18
[26] Linking nicotine addiction and T2DM
Alan Morris
[J]. Nature Reviews Endocrinology, 2020, 16 (1) : 6 - 6
[27] RAGE—a biomarker for CHD in T2DM?
Carol Wilson
[J]. Nature Reviews Endocrinology, 2011, 7 (10) : 561 - 561
[28] Antihelminthic drug for T2DM therapy?
Joana Osório
[J]. Nature Reviews Endocrinology, 2014, 10 (12) : 702 - 702
[29] Dapagliflozin—redefining treatment of T2DM?
Edward C. Chao
[J]. Nature Reviews Endocrinology, 2011, 7 : 696 - 697
[30] Shared variants for osteoporosis and T2DM
Claire Greenhill
[J]. Nature Reviews Endocrinology, 2018, 14 : 627 - 627

← 1 2 3 4 5 →